Monthly return of equity issuer on movements in securities for the month ended 30 September 2026
Filed with HKEX · Stock code 2616 · · 11 pages · English
Summary by 6ix AI
The report confirms the total authorized share capital and provides details on issued shares and treasury shares. It also includes a public float sufficiency confirmation, ensuring compliance with listing rules. The filing serves to inform stakeholders about the company's share capital movements and compliance status.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from CStone Pharmaceuticals
- Interim report 2026
- Voluntary announcement - increase in shareholding by CEO and executive director dr. jianxin yang by 496,000 shares, with accumulated purchase totaling 14,210,500 shares
- CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum
- CStone Pharmaceuticals Enters into Exclusive Commercialization Agreement with Arrotex for Sugemalimab across Australia and New Zealand
- CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) ASCO 2026 Key Highlights
Follow CStone Pharmaceuticals into a list and get an email when it puts out news.
Follow CStone Pharmaceuticals